2021-02 START-D - Safe and Timely Antithrombotic Removal – Direct Oral Anticoagulants Apixaban & Rivaroxaban (STAR-D): A Prospective, Multicenter, Double-blind, Randomized, Study DrugSorb-ATR Removal of Apixaban and Rivaroxaban to Reduce Likelih

NCT05093504

START-D - Safe and Timely Antithrombotic Removal – Direct Oral Anticoagulants Apixaban & Rivaroxaban (STAR-D): A Prospective, Multicenter, Double-blind, Randomized, Study DrugSorb-ATR Removal of Apixaban and Rivaroxaban to Reduce Likelihood of Serious Bleeding in Patients Undergoing Urgent Cardiothoracic Surgery

Associated Conditions

Structural Heart

Principal Investigator

Sponsor

CytoSorbents

The purpose of this study is to evaluate a new method for removing drugs like apixaban and rivaroxaban from the blood during heart or aortic surgery, using an adsorption (“sticky”) device called DrugSorb-ATR. The DrugSorb-ATR device is connected to the heart-lung bypass machine [also called cardiopulmonary bypass (CPB)], during surgery. (Note: The DrugSorb-ATR device is approved for use in the European Union and the United Kingdom for removing rivaroxaban from the blood during surgery, but is not approved in the United States.)